TY - JOUR
T1 - Novel Immuno-Oncology therapy
T2 - Current status of clinical research and prospect of application
AU - Zhang, Shi Jia
AU - Ren, Sheng Xiang
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Recently, immune-oncologic therapy advanced rapidly and has been defined as another option, following surgery, radiotherapy, chemotherapy and molecular targeted therapy, for treatment of malignant diseases. To date, several immune checkpoint inhibitors and compounds have been approved to treat various of malignant diseases with efficiency. Meanwhile, more and more potential therapeutic targets in processes of the cancer immunity have been noticed. We aimed to summarize the research status and clinical prospects of novel immune-oncologic treatment agencies targeted to different steps of the cancer-immunity cycle.
AB - Recently, immune-oncologic therapy advanced rapidly and has been defined as another option, following surgery, radiotherapy, chemotherapy and molecular targeted therapy, for treatment of malignant diseases. To date, several immune checkpoint inhibitors and compounds have been approved to treat various of malignant diseases with efficiency. Meanwhile, more and more potential therapeutic targets in processes of the cancer immunity have been noticed. We aimed to summarize the research status and clinical prospects of novel immune-oncologic treatment agencies targeted to different steps of the cancer-immunity cycle.
KW - Immune checkpoint inhibitor
KW - Immuno-oncology therapy
KW - Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85030115787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030115787&partnerID=8YFLogxK
U2 - 10.3779/j.issn.1009-3419.2017.09.10
DO - 10.3779/j.issn.1009-3419.2017.09.10
M3 - Article
C2 - 28935020
AN - SCOPUS:85030115787
SN - 1009-3419
VL - 20
SP - 645
EP - 651
JO - Chinese Journal of Lung Cancer
JF - Chinese Journal of Lung Cancer
IS - 9
ER -
